System Offers New Options for Improving Outcomes in Treating Stroke
- System Offers New Options for Improving Outcomes in Treating Stroke;
- World’s Second-Leading Cause of Death, Third-Leading Cause of Disability
DUBLIN - April 30, 2019 - Medtronic plc (NYSE:MDT) today announced the U.S. launch of the Solitaire(TM) X Revascularization Device - and its first use in patients for the treatment of acute ischemic stroke. For ten years, the industry-leading Solitaire(TM) Revascularization Device has enabled physicians in helping patients have a better chance at recovering from stroke. Solitaire X is a 4th generation device featuring an optimized delivery system for improved efficiency - while retaining the technical features that have made the Solitaire family of revascularization devices clinically proven and highly effective. In addition, Medtronic introduces Phenom(TM) 21 Catheter, a 160cm length microcatheter for the delivery of all sizes of Solitaire X.
The Solitaire X device mechanically removes blood clots from blocked vessels in the brain to restore blood flow in patients suffering an acute ischemic stroke with large vessel occlusion. When combined with Phenom 21, Solitaire X provides a low clot crossing profile, with smooth delivery to occlusions in distal vessels as small as 2.0mm. This compatible system reinforces Medtronic’s commitment to the fight against stroke.
“Medtronic continues to deliver technological innovations to advance stroke treatment. As a long-time Solitaire user, I am impressed with the ease of the Solitaire X delivery,” said Dr. Reza Jahan, professor of radiology and neurosurgery at UCLA. “I find that Solitaire X 6x40 device combined with Phenom 21 catheter provides smooth navigation especially when working with complicated anatomy.”
Globally, stroke is the second leading cause of death, killing nearly 6 million people each year. It is also the third leading cause of disability.1 In the United States, approximately 795,000 people suffer a stroke annually, and it is the leading cause of serious, long-term disability. In fact, in the U.S. a stroke occurs every 40 seconds,2 and every four minutes someone dies of a stroke.3
“Our commitment to enable physicians to improve outcomes for stroke patients worldwide will always be our motivation,” said Stacey Pugh, vice president and general manager of Medtronic’s Neurovascular business, which is part of the Restorative Therapies Group at Medtronic. “The net result of that commitment is the launch of a 4th generation device - Solitaire X - which marks 10 years of innovation in stroke therapy.”
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 86,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
-end-
1 World Health Organization, 2018.
2 Vital Signs: Recent trends in stroke death rates - United States, 2000-2015. MMWR 2017;66.
3 Benjamin EJ, Blaha MJ, Chiuve SE, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e229-e445.
Contacts:
David T. Young
Public Relations
+1-774-284-2746
Ryan Weispfenning
Investor Relations
+1-763-505-4626
